NovaBridge Biosciences (NASDAQ: NBP) is a Healthcare company (Biotechnology) with a market capitalization of $95M. The Maz Rating grades it against the other companies in its sector.
NovaBridge Biosciences's current Maz Rating and its five factor grades are for members: log in to see them.
At $0.82, NovaBridge Biosciences trades at 0.5x book value, with an EV/EBITDA of 1.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -1.4%, return on invested capital of -29.0% and a free cash flow yield of -37.3%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 7.64. Over the past 52 weeks the share price ranged from $0.75 to $5.19, with a beta of 1.71.
NovaBridge Biosciences does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.